menu
    • menu
    [{"orgOrder":0,"company":"Nang Kuang Pharmaceutical Co. Ltd.","sponsor":"Buddhist Tzu Chi General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Nang Kuang Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nang Kuang Pharmaceutical Co. Ltd. \/ Buddhist Tzu Chi General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Nang Kuang Pharmaceutical Co. Ltd. \/ Buddhist Tzu Chi General Hospital"},{"orgOrder":0,"company":"National Institute of Mental Health, Dhaka","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BANGLADESH","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"National Institute of Mental Health, Dhaka","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute of Mental Health, Dhaka \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"National Institute of Mental Health, Dhaka \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Kindred Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing"}]

    Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3325

    Menu

    DSSTox_CID_3325

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Institute of Mental Health, Dhaka

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            National Institute of Mental Health, Dhaka

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia

                            Details : Mirtazapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2023

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kindred Biosciences

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Kindred Biosciences

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Dechra Pharmaceuticals Manufacturing

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction

                            Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $43.0 million

                            March 16, 2020

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Dechra Pharmaceuticals Manufacturing

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nang Kuang Pharmaceutical Co. Ltd.

                            China arrow
                            AllPack Indonesia
                            Not Confirmed

                            Nang Kuang Pharmaceutical Co. Ltd.

                            China arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Buddhist Tzu Chi General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With...

                            Details : Smilon is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depression.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 10, 2010

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Buddhist Tzu Chi General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth